OBJECTIVES: Existing experimental approaches for studies of blast impact in small animals are insufficient and lacking consistency. Here, we present a comprehensive model, with repeatable blast signatures of controlled duration, peak pressure, and transmitted impulse, accurately reproducing blast impact in laboratory animals. MATERIALS: Rat survival, brain pathomorphology, and levels of putative biomarkers of brain injury glial fibrillary acid protein (GFAP), neuron-specific enolase, and ubiquitin C-terminal hydrolase (UCH)-L1 were examined in brain, cerebrospinal fluid (CSF), and blood after 10 msec of 358 kPa peak overpressure blast exposure. RESULTS: The high-speed imaging demonstrated a strong head acceleration/jolting accompanied by typical intracranial hematomas and brain swelling. Microscopic injury was revealed by prominent silver staining in deep brain areas, including the nucleus subthalamicus zone, suggesting both diffused and focal neurodegeneration. GFAP and 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase), markers of astroglia and oligodendroglia, accumulated substantially in the hippocampus 24 hours after blast and persisted for 30 days postblast. However, GFAP content in the blood significantly increased 24 hours after injury, followed by a decline and subsequent accumulation in CSF in a time-dependent fashion. A similar profile is shown for UCH-L1 increase in blood, whereas increased CSF levels of UCH-L1 persisted throughout 14 days after blast and varied significantly in individual rats. Neuron-specific enolase levels in blood were significantly elevated within 24 hours and 48 hours postblast. CONCLUSIONS: The proposed model of controlled nonpenetrating blast in rats demonstrates the critical pathologic and biochemical signatures of blast brain injury that may be triggered by cerebrovascular responses, including blood-brain barrier disruption, glia responses, and neuroglial alterations.
OBJECTIVES: Existing experimental approaches for studies of blast impact in small animals are insufficient and lacking consistency. Here, we present a comprehensive model, with repeatable blast signatures of controlled duration, peak pressure, and transmitted impulse, accurately reproducing blast impact in laboratory animals. MATERIALS: Rat survival, brain pathomorphology, and levels of putative biomarkers of brain injuryglial fibrillary acid protein (GFAP), neuron-specific enolase, and ubiquitin C-terminal hydrolase (UCH)-L1 were examined in brain, cerebrospinal fluid (CSF), and blood after 10 msec of 358 kPa peak overpressure blast exposure. RESULTS: The high-speed imaging demonstrated a strong head acceleration/jolting accompanied by typical intracranial hematomas and brain swelling. Microscopic injury was revealed by prominent silver staining in deep brain areas, including the nucleus subthalamicus zone, suggesting both diffused and focal neurodegeneration. GFAP and 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase), markers of astroglia and oligodendroglia, accumulated substantially in the hippocampus 24 hours after blast and persisted for 30 days postblast. However, GFAP content in the blood significantly increased 24 hours after injury, followed by a decline and subsequent accumulation in CSF in a time-dependent fashion. A similar profile is shown for UCH-L1 increase in blood, whereas increased CSF levels of UCH-L1 persisted throughout 14 days after blast and varied significantly in individual rats. Neuron-specific enolase levels in blood were significantly elevated within 24 hours and 48 hours postblast. CONCLUSIONS: The proposed model of controlled nonpenetrating blast in rats demonstrates the critical pathologic and biochemical signatures of blast brain injury that may be triggered by cerebrovascular responses, including blood-brain barrier disruption, glia responses, and neuroglial alterations.
Authors: Lee E Goldstein; Andrew M Fisher; Chad A Tagge; Xiao-Lei Zhang; Libor Velisek; John A Sullivan; Chirag Upreti; Jonathan M Kracht; Maria Ericsson; Mark W Wojnarowicz; Cezar J Goletiani; Giorgi M Maglakelidze; Noel Casey; Juliet A Moncaster; Olga Minaeva; Robert D Moir; Christopher J Nowinski; Robert A Stern; Robert C Cantu; James Geiling; Jan K Blusztajn; Benjamin L Wolozin; Tsuneya Ikezu; Thor D Stein; Andrew E Budson; Neil W Kowall; David Chargin; Andre Sharon; Sudad Saman; Garth F Hall; William C Moss; Robin O Cleveland; Rudolph E Tanzi; Patric K Stanton; Ann C McKee Journal: Sci Transl Med Date: 2012-05-16 Impact factor: 17.956
Authors: Elliot J Glotfelty; Thomas Delgado; Luis B Tovar-Y-Romo; Yu Luo; Barry Hoffer; Lars Olson; Tobias Karlsson; Mark P Mattson; Brandon Harvey; David Tweedie; Yazhou Li; Nigel H Greig Journal: ACS Pharmacol Transl Sci Date: 2019-02-11
Authors: Matthew Beamer; Shanti R Tummala; David Gullotti; Catherine Kopil; Samuel Gorka; Cameron R Dale Bass; Barclay Morrison; Akiva S Cohen; David F Meaney Journal: Exp Neurol Date: 2016-05-28 Impact factor: 5.330
Authors: Victor Prima; Victor L Serebruany; Artem Svetlov; Ronald L Hayes; Stanislav I Svetlov Journal: J Neurotrauma Date: 2013-10-04 Impact factor: 5.269
Authors: George J Arnaoutakis; Timothy J George; Kevin K Wang; Mary Ann Wilson; Jeremiah G Allen; Chase W Robinson; Kara A Haggerty; Eric S Weiss; Mary E Blue; Charles C Talbot; Juan C Troncoso; Michael V Johnston; William A Baumgartner Journal: J Thorac Cardiovasc Surg Date: 2011-10 Impact factor: 5.209
Authors: Zhiqun Zhang; Stefania Mondello; Firas Kobeissy; Richard Rubenstein; Jackson Streeter; Ronald L Hayes; Kevin K W Wang Journal: Transl Stroke Res Date: 2011-12-07 Impact factor: 6.829
Authors: Corina O Bondi; Bridgette D Semple; Linda J Noble-Haeusslein; Nicole D Osier; Shaun W Carlson; C Edward Dixon; Christopher C Giza; Anthony E Kline Journal: Neurosci Biobehav Rev Date: 2014-12-10 Impact factor: 8.989
Authors: Patrick M Kochanek; C Edward Dixon; David K Shellington; Samuel S Shin; Hülya Bayır; Edwin K Jackson; Valerian E Kagan; Hong Q Yan; Peter V Swauger; Steven A Parks; David V Ritzel; Richard Bauman; Robert S B Clark; Robert H Garman; Faris Bandak; Geoffrey Ling; Larry W Jenkins Journal: J Neurotrauma Date: 2013-06-05 Impact factor: 5.269